PERCEPTIVE ADVISORS LLC 13D and 13G filings for Amylyx Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 4:15 pm Purchase |
2024-12-31 | 13G | Amylyx Pharmaceuticals, Inc. AMLX |
PERCEPTIVE ADVISORS LLC | 6,774,348 7.900% |
2,315,607 (+51.93%) |
Filing |
| 2024-10-25 5:38 pm Purchase |
2024-10-18 | 13G | Amylyx Pharmaceuticals, Inc. AMLX |
PERCEPTIVE ADVISORS LLC | 4,458,741 6.500% |
2,589,616 (+138.55%) |
Filing |
| 2024-02-14 4:36 pm Sale |
2023-12-31 | 13G | Amylyx Pharmaceuticals, Inc. AMLX |
PERCEPTIVE ADVISORS LLC | 1,869,125 2.800% |
-4,219,208 (-69.30%) |
Filing |
| 2023-02-14 2:33 pm Purchase |
2022-12-31 | 13G | Amylyx Pharmaceuticals, Inc. AMLX |
PERCEPTIVE ADVISORS LLC | 6,088,333 9.200% |
3,116,920 (+104.90%) |
Filing |
| 2022-06-21 09:07 am Purchase |
2022-06-08 | 13G | Amylyx Pharmaceuticals, Inc. AMLX |
PERCEPTIVE ADVISORS LLC | 2,971,413 5.100% |
2,971,413 (New Position) |
Filing |